AbbVie: Carcinoma, Ovarian Epithelial trials

The registry lists 10 Carcinoma, Ovarian Epithelial studies with AbbVie as lead sponsor. 1 are open to participants now and 4 have results posted.

Phase 1 5Phase 2 4Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.RecruitingNCT06890338Phase 2
• A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionCompletedNCT04296890Phase 3Results posted
• A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) ExpressionCompletedNCT04209855Phase 3Results posted
• A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube CancerCompletedNCT02631876Phase 3Results posted
• Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02606305Phase 1/2Results posted
• A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian CancerWithdrawnNCT03400306Phase 1
• Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian CancerTerminatedNCT02539719Phase 1
• Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian CancerCompletedNCT02483104Phase 1
• A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian CancerCompletedNCT01113957Phase 2
• Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)CompletedNCT00635193Phase 1/2